Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090191 · ClinicalTrials.gov registry record · Phase 3
Clostridium Difficile Vaccine Efficacy Trial
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 17,535
- Enrollment target
NCT03090191 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 17,535 participants.
The verdict
NCT03090191, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 17,535 participants
- Enrollment target
Study Summary
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the disease, and whether it is safe and well tolerated. Each subject will receive 3 doses of Clostridium difficile vaccine or placebo and be followed for up to 3 years after vaccination for potential Clostridium difficile infection.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Clostridium difficile vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,535 participants |
| Start Date | 2017-03-29 |
| Est. Completion | 2021-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03090191
The ClinicalTrials.gov registry entry for NCT03090191 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 17,535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03090191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03090191 about?
NCT03090191 is a clinical study titled "Clostridium Difficile Vaccine Efficacy Trial". The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium difficile infection. The study will assess whether the vaccine prevents the di...
What is the current status of trial NCT03090191?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 17,535 participants. The study started on 2017-03-29. Estimated completion is 2021-12-21.
What interventions are being tested in trial NCT03090191?
The interventions under investigation include: Placebo (BIOLOGICAL), Clostridium difficile vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03090191?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.